Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 05, 2024 (filed on Apr 09, 2024)Insider Name:Gala Renee DOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,736Price:$115.21
-
Mar 07, 2024 (filed on Mar 08, 2024)Insider Name:Carr PatriciaOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,768Price:$116.98
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Carr PatriciaOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-700Price:$117.51
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Carr PatriciaOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,236Price:$120.85
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Gala Renee DOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,622Price:$117.53
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Pearce SamanthaOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,474Price:$117.53
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Patil Neena MOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,432Price:$117.53
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Iannone RobertOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,294Price:$117.53
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Cozadd Bruce COwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-22,436Price:$117.53
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Henderson Mary ElizabethOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,178Price:--
Filings by filing date
-
Apr 05, 2024 (filed on Apr 09, 2024)Insider Name:Gala Renee DOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-1,736Price:$115.21
-
Mar 07, 2024 (filed on Mar 08, 2024)Insider Name:Carr PatriciaOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,768Price:$116.98
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Carr PatriciaOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-700Price:$117.51
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Carr PatriciaOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,236Price:$120.85
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Gala Renee DOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,622Price:$117.53
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Pearce SamanthaOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,474Price:$117.53
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Patil Neena MOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,432Price:$117.53
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Iannone RobertOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,294Price:$117.53
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Cozadd Bruce COwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-22,436Price:$117.53
-
Mar 01, 2024 (filed on Mar 05, 2024)Insider Name:Henderson Mary ElizabethOwnership Type:Direct OwnershipSecurities:Ordinary SharesNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,178Price:--
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Fifth Fl Waterloo Exchange, Waterloo Road DUBLIN 4 |
Tel: | 1-650-4962717 |
Website: | https://www.jazzpharma.com |
IR: | See website |
Key People | ||
Bruce C. Cozadd Chairman of the Board, Chief Executive Officer | Renee D. Gala President, Chief Operating Officer | Philip Johnson Chief Financial Officer, Executive Vice President |
Robert Iannone Executive Vice President, Global Head of Research and Development | Neena M. Patil Executive Vice President, Chief Legal Officer | Patricia Carr Senior Vice President, Chief Accounting Officer |
Finbar Larkin Senior Vice President - Technical Operations | Samantha Pearce Senior Vice President, Europe and International |
Business Overview |
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company's lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD). |
Financial Overview |
For the fiscal year ended 31 December 2023, Jazz Pharmaceuticals PLC revenues increased 5% to $3.83B. Net income totaled $414.8M vs. loss of $224.1M. Revenues reflect Xyrem segment increase of 37% to $2.71B, Rylaze segment increase of 40% to $394.2M, United States segment increase of 4% to $3.49B, Europe segment increase of 12% to $269.2M. Net Income reflects Acquired in-process research and develop decrease of 96% to $19M (expense). |
Employees: | 2,800 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $10,916M as of Dec 31, 2023 |
Annual revenue (TTM): | $3,834M as of Dec 31, 2023 |
EBITDA (TTM): | $1,217M as of Dec 31, 2023 |
Net annual income (TTM): | $414.83M as of Dec 31, 2023 |
Free cash flow (TTM): | $1,049M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $4,092M as of Dec 31, 2023 |
Shares outstanding: | 62,345,283 as of Feb 21, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |